Last reviewed · How we verify

Atovaquone Proguanil and Artesunate Mefloquine

Armed Forces Research Institute of Medical Sciences, Thailand · FDA-approved active Small molecule Quality 3/100

Atovaquone Proguanil and Artesunate Mefloquine is a Small molecule drug developed by Armed Forces Research Institute of Medical Sciences, Thailand. It is currently FDA-approved.

At a glance

Generic nameAtovaquone Proguanil and Artesunate Mefloquine
SponsorArmed Forces Research Institute of Medical Sciences, Thailand
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atovaquone Proguanil and Artesunate Mefloquine

What is Atovaquone Proguanil and Artesunate Mefloquine?

Atovaquone Proguanil and Artesunate Mefloquine is a Small molecule drug developed by Armed Forces Research Institute of Medical Sciences, Thailand.

Who makes Atovaquone Proguanil and Artesunate Mefloquine?

Atovaquone Proguanil and Artesunate Mefloquine is developed and marketed by Armed Forces Research Institute of Medical Sciences, Thailand (see full Armed Forces Research Institute of Medical Sciences, Thailand pipeline at /company/armed-forces-research-institute-of-medical-sciences-thailand).

What development phase is Atovaquone Proguanil and Artesunate Mefloquine in?

Atovaquone Proguanil and Artesunate Mefloquine is FDA-approved (marketed).

Related